JPRN-UMIN000016256已完成未知
A phase II study of capecitabin plus oxaliplatin therapy (XELOX) for inoperable/advanced gastric cancer resistant/intolerable to fluoro-pyrimidine, CDDP, Taxane or CPT-11 (OGSG1403) - A phase II study of capecitabin plus oxaliplatin therapy (XELOX) for inoperable/advanced gastric cancer resistant/intolerable to fluoro-pyrimidine, CDDP, Taxane or CPT-11 (OGSG1403)
Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)0 个研究点目标入组 12 人开始时间: 2015年1月19日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)With prior chemotherapy including oxaliplatin (L-OHP) 2)With some active double cancers 3)With severe complications 4)With active infectious diseases which need treatments 5)With thoracic fluid and/or ascites which need drainage 6)under continuous steroids medication 7)under medication of phenytoin and/or warfarin 8)with active bleeding which needs frequent blood transfusion 9)with central nerve metastases with symptoms 10) with psychological disorders 11) Pregnant and/or nursing women or men who like to have children 12)Any other patients whom the physician in charge of the study judges to be unsuitable
研究者
相似试验
已完成
不适用
Phase II study of Capecitabine + oxaliplatin(CapeOx) for elderly patients with untreated metastatic gastric cancer <TCOG GI-1601>ntreated metastatic gastric cancerJPRN-UMIN000022450The Tokyo Cooperative Oncology Group110
已完成
2 期
P II study of CapeOX therapy for small intestinal cancerunresectable or recurrent small bowel adenocarcinoma with no prior treatmentJPRN-jRCTs041180011Yasui Hirofumi17
已完成
不适用
A Phase II Study of Capecitabine, Oxaliplatin (XELOX) and Bevacizumab for patient with high-risk Upper Rectal Cancer as Neo-Adjuvant chemotherapy.pper rectal cancerJPRN-UMIN000015765Cancer Institute Hospital of Japanese Foundation for Cancer Research19
招募中
2 期
A phase II trial of oxaliplatin, capecitabine, irinotecan (XELOXIRI) and bevacizumab as first-line therapy for patients with metastatic colorectal cancermetastatic colorectal cancerJPRN-UMIN000039783Sapporo Medical University School of Medicine47
招募中
4 期
Cohort study of capecitabine plus oxaliplatin (XELOX) together with Bevacizumab as the first-line therapy in advance or recurrent colorectal cancer.Advance or recurrent colorectal cancer.JPRN-UMIN000006057Tokyo Medical University The third department of surgery30